The American Journal of Human Genetics, 91

Supplemental Data

Large-Scale Gene-Centric Meta-analysis

across 32 Studies Identifies Multiple Lipid Loci

Folkert W. Asselbergs, Yiran Guo, Erik P.A. van Iperen, Suthesh Sivapalaratnam, Vinicius Tragante, Matthew B. Lanktree, Leslie A. Lange, Berta Almoguera, Yolande E. Appelman, John Barnard, Jens Baumert, Amber L. Beitelshees, Tushar R. Bhangale, Yii-Der Ida Chen, Tom R. Gaunt, Yan Gong, Jemma C Hopewell, Toby Johnson, Marcus E. Kleber, Taimour Y. Langaee, Mingyao Li, Yun R. Li, Kiang Liu, Caitrin W McDonough, Matthijs F.L. Meijs, Rita P.S. Middelberg, Kiran Musunuru, Christopher P. Nelson, Jeffery R. O'Connell, Sandosh Padmanabhan, James S. Pankow, Nathan Pankratz, Suzanne Rafelt, Ramakrishnan Rajagopalan, Simon P.R. Romaine, Nicholas J. Schork, Jonathan Shaffer, Haiqing Shen, Erin N. Smith, Sam E. Tischfield, Peter J. van der Most, Jana V. van Vliet-Ostaptchouk, Niek Verweij, Kelly A. Volcik, Li Zhang, Kent R. Bailey, Kristian M. Bailey, Florianne Bauer, Jolanda M.A. Boer, Peter S. Braund, Amber Burt, Paul R. Burton, Sarah G. Buxbaum, Wei Chen, Rhonda M. Cooper-DeHoff, L. Adrienne Cupples, Jonas S. deJong, Christian Delles, David Duggan, Myriam Fornage, Clement E. Furlong, Nicole Glazer, John G. Gums, Claire Hastie, Michael V. Holmes, Thomas Illig, Susan A. Kirkland, Mika Kivimaki, Ronald Klein, Barbara E. Klein, Charles Kooperberg, Kandice Kottke-Marchant, Meena Kumari, Andrea Z. LaCroix, Laya Mallela, Gurunathan Murugesan, Jose Ordovas, Willem H. Ouwehand, Wendy S. Post, Richa Saxena, Hubert Scharnagl, Pamela J. Schreiner, Tina Shah, Denis C. Shields, Daichi Shimbo, Sathanur R. Srinivasan, Ronald P. Stolk, Daniel I. Swerdlow, Herman A. Taylor, Jr., Eric J. Topol, Elina Toskala, Joost L. van Pelt, Jessica van Setten, Salim Yusuf, John C. Whittaker, A.H. Zwinderman, LifeLines Cohort Study, Sonia S. Anand, Anthony J. Balmforth, Gerald S. Berenson, Connie R. Bezzina, Bernhard O. Boehm, Eric Boerwinkle, Juan P. Casas, Mark J. Caulfield, Robert Clarke, John M. Connell, Karen J. Cruickshanks, Karina W. Davidson, Ian N.M. Day, Paul I.W. de Bakker, Pieter A. Doevendans, Anna F. Dominiczak, Alistair S. Hall, Catharina A. Hartman, Christian Hengstenberg, Hans L. Hillege, Marten H. Hofker, Steve E. Humphries, Gail P. Jarvik, Julie A. Johnson, Bernhard M. Kaess, Sekar Kathiresan, Wolfgang Koenig, Debbie A. Lawlor, Winfried März, Olle Melander, Braxton D. Mitchell, Grant W. Montgomery, Patricia B. Munroe, Sarah S. Murray, Stephen J. Newhouse, N. Charlotte Onland-Moret, Neil Poulter, Bruce Psaty, Susan Redline, Stephen S. Rich, Jerome I. Rotter, Heribert Schunkert, Peter Sever, Alan R. Shuldiner, Roy L. Silverstein, Alice Stanton, Barbara Thorand, Mieke D. Trip, Michael Y. Tsai, Pim van der Harst, Ellen van der Schoot, Yvonne T. van der Schouw, W.M. Monique Verschuren, Hugh Watkins, Arthur A.M. Wilde, Bruce H.R. Wolffenbuttel, John B. Whitfield, G. Kees Hovingh, Christie M. Ballantyne, Cisca Wijmenga, Muredach P. Reilly, Nicholas G. Martin, James G. Wilson, Daniel J. Rader, Nilesh J. Samani, Alex P. Reiner, Robert A. Hegele, John J.P. Kastelein, Aroon D. Hingorani, Philippa J. Talmud, Hakon Hakonarson, Clara C. Elbers, Brendan J. Keating, and Fotios Drenos

Supplemental Acknowledgments

Discovery Cohort Acknowledgments

<u>AGNES</u>: The AGNES study is supported by the Netherlands Heart Foundation (2001D019, 2003T302 and 2007B202), the Leducq Foundation (grant 05-CVD) and CTMM-COHFAR, and Bloodomics (LSHM-CT-2004-503485).

<u>AIBIII</u>: The Allied Irish Bank workers III :study was supported by the Higher Education Authority (Ireland), Programme for research in Third-Level Institutions Cycle 3, Programme for Human Genomics. We thank the Allied Irish Bank and their employees for facilitating the study.

AMC-PAS: Funding for PAS was provided by Ipse Movet; Bloodomics (LSHM-CT-2004-503485).

<u>Amish</u>: The Amish studies were supported by NIH research grants R01 HL088119, R01 AG18728, and U01 HL72515, an American Heart Association Scientist Development Grant (0830146N to HS), with additional funding provided by the Mid-Atlantic Nutrition Obesity Research Center (P30 DK072488).

ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Atherosclerotic Risk in Communities: University of North Carolina at Chapel Hill (N01-HC-55015, N01-HC-55018), Baylor Medical College(N01-HC-55016), University of Mississippi Medical Center(N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas, Houston (N01-HC-55022). The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

<u>ASCOT</u>: This work was supported by Pfizer, New York, NY, USA, for the ASCOT study and the collection of the ASCOT DNA repository; by Servier Research Group, Paris, France; and by Leo Laboratories, Copenhagen, Denmark. We thank all ASCOT trial participants, physicians, nurses, and practices in the participating countries for their important contribution to the study. In particular we thank Clare Muckian and David Toomey for their help in DNA extraction, storage, and handling.

<u>BHS</u>: ENS, SSM, and NJS are supported in part by NIH/NCRR Grant Number UL1 RR025774. The BHS was supported by grants HD-061437 and HD-062783 from the National Institute of Child Health and Human Development, and AG-16592 from the National Institute on Aging.

<u>BRIGHT</u>: "This work was supported by the Medical Research Council of Great Britain (grant number G9521010D); and by the British Heart Foundation (grant number PG/02/128). A.F.D. was supported by the British Heart Foundation (grant numbers RG/07/005/23633, SP/08/005/25115); and by the European Union Ingenious HyperCare Consortium: Integrated Genomics, Clinical Research, and Care in Hypertension (grant number LSHM-C7-2006-037093). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. We would also like to thank the Barts Genome Centre staff for their assistance with this project. This work forms part of the research themes contributing to the translational research portfolio for Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institute for Health Research.

<u>BWHHS</u>: The British Women's Heart and Health Study is supported by funding from the British Heart Foundation and the Department of Health Policy Research Programme (England). We thank the BWHHS data collection team, General Practitioners who helped with recruitment of participants and the participants. We thank all of the participants and the general practitioners, research nurses and data management staff who supported data collection and preparation. The BWHHS is coordinated by Shah Ebrahim (PI), Debbie Lawlor and Juan-Pablo Casas, with genotyping funded by the BHF (PG/07/131/24254, PI Tom Gaunt). The BRIGHT study was supported by the Medical Research Council of Great Britain (G9521010D) and the British Heart Foundation. (PG/02/128).

<u>CARDIA</u>: Coronary Artery Risk in Young Adults: University of Alabama at Birmingham (N01-HC-48047, N01-HC-95095), University of Minnesota (N01-HC-48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), University of California, Irvine (N01-HC-45134, N01-HC-95100)

<u>CHS</u>: Cardiovascular Health Study: University of Washington (N01-HC-85079, N01-HC-55222, U01-HL-080295), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081, N01-HC-15103), University of Pittsburgh (N01-HC-85082), University of California, Davis (N01-HC-85083), University of California, Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-35129), University of Wisconsin (N01-HC-75150)

<u>CLEAR</u>: CLEAR support (GPJ) came from R01 HL67406, the Northwest Institute of Genetic Medicine, and the State of Washington Life Sciences Discovery Fund. The CLEAR investigators sincerely thank the participants for their efforts.

<u>CLEVELAND CLINIC/GeneQuest 2</u>: CCGQ2 was supported by grant P50HL81011 from the National Heart, Lung and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services.

<u>BOSS</u>: BOSS was supported by R01AG021917 (KJC) from the National Institute on Aging, National Eye Institute, and National Institute on Deafness and Other Communication Disorders, EHLS was supported by R37AG11099 (KJC) from the National Institute on Aging, and BDES was supported by U10EY06594 (Klein R and Klein BEKK) from the National Eye Institute. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institute on Aging or the National Institutes of Health.

<u>EPIC-NL</u>: The EPIC-NL study was funded by 'Europe against Cancer' Programme of the European Commission (SANCO), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch Cancer Society; ZonMW the Netherlands Organisation for Health Research and Development, World Cancer Research Fund (WCRF) (The Netherlands). Genotyping of the IBC-chip was funded by IOP Genomics grant IGE05012 from NL Agency.

<u>FHS</u>: The Framingham Heart Study research included in this study is funded by NIH grant/contract N01-HC-25195, R01-HL-092577, R01-HL-076784, R01-AG-028321, and by the NIH Intramural Research Program.

GIRaFH: GIRaFH wishes to sincerely thank the participants and staff that contributed to the study.

<u>GRAPHIC</u>: This work was supported by the British Heart Foundation (grant numbers RG/2001004, PG/07/132/24256) for recruitment and genotyping of the GRAPHIC cohort. N.J.S. was supported by a British Heart Foundation Chair of Cardiology (grant number CH/03/001. This study is part of the research portfolio supported by the Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease.

<u>HHDL</u> gratefully acknowledge internal funding from the University of Pennsylvania and the participation of the study subject and are indebted to the investigators on these teams.

<u>MONICA/KORA</u>: The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFNplus, project number 01GS0834), by the German Research Foundation (TH-784/2-1 and TH-784/2-2), by the European Foundation for the Study of Diabetes and through additional funds from the Helmholtz Zentrum München, the German Diabetes Center and the University of Ulm. Furthermore, the research was supported within the Munich Center of Health Sciences (MC Health) as part of the Ludwig Maximilians University (LMU) innovative.

<u>LURIC</u>: LURIC thanks their participants and researchers and acknowledges that it has received funding trough the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and 7th of Framework Program (integrated project Atheroremo, Grant Agreement number 201668) of the European Union.

<u>MESA</u>: Multi-Ethnic Study of Atherosclerosis: University of Washington (N01-HC-95159), University of California, Los Angeles (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162, N01-HC-95168), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Harbor-UCLA Research and Education Institute (N01-HC-95169), Cedars-Sinai Medical Center (R01-HL-071205), University of Virginia

<u>NORDIL</u>: This work was supported by the British Heart Foundation (grant number CH/98001 to A.F.D., RG/07/005/23633 to A.F.D., S.P. and C.D.) and a Special Project, for genotyping of the Swedish extremes from the NORDIL and MDC cohorts; and by Pharmacia. We thank Professor Thomas Hedner (Department of Clinical Pharmacology, Sahlgrenska Academy, Gotheburg, Sweden) and Professor Sverre Kjeldsen (Ullevaal University Hospital, University of Oslo, Oslo, Norway), who are investigators of the NORDIL study. Professor Kjeldsen is also an investigator of the ASCOT trial.

<u>PEAR</u>: PEAR was supported by the National Institute of Health Pharmacogenetics Research Network grant U01-GM074492 and the National Center for Advancing Translational Sciences under the award number UL1 TR000064 (University of Florida); UL1 TR000454 (Emory University) and UL1 TR000135 (Mayo Clinic) and funds from the Mayo Foundation.

<u>PennCAC</u>: The University of Pennsylvania Coronary Artery Calcification Study (PennCAC) gratefully acknowledge internal funding from the University of Pennsylvania and the participation of the study subject and are indebted to the investigators on these teams.

<u>PennCath</u>: The University of Pennsylvania Catheterization study program (PennCATH) gratefully acknowledge internal funding from the University of Pennsylvania and the participation of the study subject and are indebted to the investigators on these teams.

<u>PROCARDIS</u>: The PROCARDIS study is supported by the British Heart Foundation, the European Community Sixth Framework Program (LSHM-CT-2007-037273), AstraZeneca, the Wellcome Trust and the United Kingdom MedicalResearch Council. Jemma C Hopewell acknowledges support from the BHF Centre of Research Excellence, Oxford.

<u>SHARE</u>: RAH was supported by the Heart and Stroke Foundation of Canada, CIHR and Genome Canada through the Ontario Genomics Institute. SSA holds the Heart and Stroke Foundation of Canada Chair in Population Health Research and a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease.

<u>SMART</u>: Folkert W. Asselbergs is supported by a clinical fellowship from the Netherlands Organisation for Health Research and Development (ZonMw grant 90700342). M.F.L.M. was financially supported by EUGeneHeart, grant number LSHM-CT-2005-018833. The authors acknowledge all MR technicians, research nurses and medical students involved in SMART Heart for valuable support.

<u>SPACEROCKET/GEOSTAT</u>: GEOSTAT was directly supported by the Leeds Teaching Hospitals Charitable Foundation, the Leeds Undergraduate Research Enterprise (LURE) funded by Heart Research UK, and the Jean Shanks Foundation. The main SPACE ROCKET Trial was supported by an unrestricted Educational Grant from AstraZeneca UK Ltd. We acknowledge the essential work of all the clinical investigators and clinical research nurses involved.

<u>WHI</u>: The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.

<u>WHII</u>: This work was supported by the British Heart Foundation (grant numbers PG/07/133/24260, RG/08/008, SP/07/007/23671), Senior Fellowship to A.D.H. (grant number FS/2005/125), Chair for S.E.H.; by the National Heart Lung and Blood Institute (grant number HL36310) for M.Kivimaki's and M.Kumari's contributions to this work; by the Medical Research Council (grant number G0802432) Population Health Scientist Fellowship to M.V.H.; by the Health and Safety Executive; by the Department of Health; by the National Institute on Aging in the United States (grant number AG13196); by the Agency for Health Care Policy Research (grant number HS06516); by the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. Michael V Holmes is funded by a Medical Research Council (UK) Population Health Scientist Fellowship (G0802432).

Replication Cohort Acknowledgments

TRAILS: TRAILS (Tracking Adolescents' Individual Lives Survey) is a collaborative project involving various departments of the University Medical Center and University of Groningen, the Erasmus University Medical Center Rotterdam, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grants 60-60600-98-018 and 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 457-03-018, GB-MaGW 452-04-314, and GB-MaGW 452-06-004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013); the Sophia Foundation for Medical Research (projects 301 and 393), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), and the participating universities. We are grateful to all adolescents, their parents and teachers who participated in this research and to everyone who worked on this project and made it possible. Statistical analyses were carried out on the Genetic Cluster Computer

(http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation.

<u>Lifelines</u>: The LifeLines Cohort Study, and generation and management of GWAS genotype data for the LifeLines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation.

We thank Behrooz Alizadeh, Annemieke Boesjes, Marcel Bruinenberg, Noortje Festen, Ilja Nolte, Lude Franke, Mitra Valimohammadi for their help in creating the GWAS database, and Rob Bieringa, Joost Keers, René Oostergo, Rosalie Visser, Judith Vonk for their work related to data-collection and validation. The authors are grateful to the study participants, the staff from the LifeLines Cohort Study and Medical Biobank Northern Netherlands, and the participating general practitioners and pharmacists. LifeLines Scientific Protocol Preparation: Rudolf de Boer, Hans Hillege, Melanie van der Klauw, Gerjan Navis, Hans Ormel, Dirkje Postma, Judith Rosmalen, Joris Slaets, Ronald Stolk, Bruce Wolffenbuttel; LifeLines GWAS Working Group: Behrooz Alizadeh, Marike Boezen, Marcel Bruinenberg, Noortje Festen, Lude Franke, Pim van der Harst, Gerjan Navis, Dirkje Postma, Harold Snieder, Cisca Wijmenga, Bruce Wolffenbuttel.

<u>AUSTWIN</u>: We acknowledge the contributions of many staff in the Genetic Epidemiology Unit, Queensland Institute of Medical Research, in interviewing study participants, sample processing and DNA extraction, and data management. Funding for aspects of this work was provided by the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498), the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921), the EU 5th Framework Programme GenomEUtwin Project (QLG2-CT-2002-01254), and the U.S. National Institutes of Health (AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, MH66206). A portion of the genotyping on which this study was based was carried out at the Center for Inherited Disease Research, Baltimore (CIDR) (Illumina 370K scans on 4300 individuals), through an access award to our late colleague Dr. Richard Todd. Parts of the statistical analyses were carried out on the Genetic Cluster Computer, which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003). R.P.S.M. and G.W.M. are supported by National Health and Medical Research Council (NHMRC) Fellowship Scheme.

<u>NSHS95</u>: Nova Scotia Health Survey 1995 (NSHS95) was supported by grants by HL-091099, HL-080665, HL-076857, HL-084034, HL-088117, HL-07854, and HL-072866 from the NHLBI; by the National Health and Welfare of Canada, Ottawa, Ontario; by the Nova Scotia Department of Health, Halifax; and by the Heart and Stroke Foundation of New Brunswick, Saint John

<u>PREVEND</u>: PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the National Institutes of Health (grant LM010098), The Netherlands organisation for health research and development (NWO VENI grant 916.761.70), and the Dutch Inter University Cardiology Institute Netherlands (ICIN).

Computing Acknowledgments

The authors acknowledge the use of the UCL Legion High Performance Computing Facility, and associated support services, in the completion of this work.




Figure S1. Heat Map Summarizing the Signals Identified from the International IBC Lipid Meta-analysis and Their Relationship with All Four, HDL-C, LDL-C, TC, and TG Phenotypes Tested

Only SNPs significant at the array wide p value threshold of 2.4×10^{-6} and filtered for heterogeneity <35% are shown.